timothy sykes logo
Goldman Sachs Sees Positive Outlook for Immunome with $26 Price Target Thumbnail
ADD US ONG Google News

Goldman Sachs Sees Positive Outlook for Immunome with $26 Price Target

BRYCE TUOHEY•UPDATED SEP. 28, 2025, 12:16 PM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

In the wake of breakthrough cancer treatment progress, Immunome Inc.’s stocks have been trading up by 15.2 percent.

Healthcare industry expert:

Analyst sentiment – positive

Immunome (IMNM) operates at the intersection of healthcare and biotechnology, yet faces substantial profitability challenges, evident from negative ebit and profit margins exceeding -1500%. Despite generating $9.04 million in revenue, these figures starkly contrast due to the disproportionate costs associated with R&D and other operational expenses. The significant market valuation reflected in an enterprise value of approximately $745 million underscores investor expectations, yet a price-to-sales ratio of 80.14 suggests an overvaluation amid current financial drawbacks. Operational liabilities are minimal, with a long-term debt to equity ratio of 0.02, and a robust liquidity position indicated by a current ratio of 12.1. However, negatives like a -75.9% return on assets hinder overall financial health.

The recent technical analysis reveals a volatile trading pattern with significant price fluctuations. Over the week, IMNM’s stock opened at $9.77 and closed at $11.6988, witnessing an upward momentum from midweek lows around $10.28. The predominant trend indicates bullish behavior, as prices demonstrate a steady climb, suggesting rising investor interest or speculative activity related to upcoming catalysts. A trading strategy should focus on capturing the upside potential on breaks above $11.70, supported by the observed resistance level at this point. Volume patterns also suggest holding a bullish stance, with increased trading volume accompanying upward price movements, reinforcing this breakout level as a key actionable entry point for short-term traders seeking to capitalize on momentum.

Catalysts involving Immunome emphasize pivotal developments. Recent collaborations, such as the agreement with Infinimmune and positive coverage from industry leaders like Goldman Sachs and Craig-Hallum, point to potentially transformative outcomes. Both firms have issued buy ratings with a $26 price target, emphasizing imminent trial results for pivotal products, such as those targeting desmoid tumors. Market performance, however, remains mixed against broader biotech benchmarks. Nonetheless, if Immunome successfully leverages its collaborations and achieves positive trial results, its stock could outperform its sector peers substantially. Current analyst coverage projecting upside momentum sets clear support at $10 with resistance at $13.50, framing a favorable risk-reward outlook contingent on forthcoming trial success. Overall, the prospects incline towards a positive sentiment, hinging on favorable trial results and execution of their strategic partnerships.

Candlestick Chart

Weekly Update Sep 22 – Sep 26, 2025: On Sunday, September 28, 2025 Immunome Inc. stock [NASDAQ: IMNM] is trending up by 15.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Immunome Inc. is currently witnessing rising investor confidence boosted by optimistic analyst coverage and robust financial metrics. The biotech company’s second quarter analysis reveals key insights into their financial rigor and growth challenges. Their revenue stands at approximately $9.04M. However, significant negative earnings with low profitability metrics, such as an EBIT margin at -1784.1%, highlight areas of concern. The company reports a current ratio of 12.1 and an impressive quick ratio of 11.7, signaling strong liquidity positions. Long-term debt to capital is low, at just 0.02, reflecting either prudent financial management practices or low leverage in growth pursuits.

More Breaking News

Stock prices indicate positive fluctuations. From a close of $10.28 on 25 September, the stock climbed to $11.6988 by the end of 26 September. This mirrors the enthusiasm emanating from recent stock ratings and partnership developments. A notable price jump on September 23 saw the stock move from an opening of $10.56 to closing at $10.55, hinting at market volatility and responding optimism likely catalyzed by the recent news.

Conclusion

Immunome is on the trajectory of upward momentum, yet it is undeniably marked by financial demands and market expectations for its pipeline’s success. While Goldman Sachs and Craig-Hallum swell investor enthusiasm with their buy ratings and price targets, the decisive turns lie in upcoming clinical outcomes. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This mindset is crucial for traders who are eyeing IMNM not just for the potential seen in foreseen product successes but also for the company’s adept strategic partnerships. Traders should watch for clinical results, market response to expanding therapeutic offerings, and how Immunome strategically aligns its financial resources to sustain its growth narrative in the biotech landscape.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IMNM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”